Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous Carcinomas Phio Pharmaceuticals Corp.

Inventus Expands Pardo With Strong Drill Results and Advances Multiple Gold Layers Toward a Maiden Resource

TORONTO, ON / ACCESS Newswire / April 1, 2026 / Inventus Mining Corp. (TSXV:IVS) ("Inventus" or the "Company")is ...